This systematic review and meta-analysis investigated whether honey-related treatment strategies improve the signs and symptoms of patients with dry eye disease (DED). In March 2023, the following databases were accessed for clinical trials investigating the efficacy of honey-related treatment strategies in DED: PubMed, Web of Science, Google Scholar, and EMBASE. The following data were extracted at baseline and at the last follow-up: Ocular Surface Disease Index, tear breakup time, Schirmer I test, and corneal staining. Data from 323 patients were retrieved (53.3% female, mean age 40.6 +/- 18.1 years). The mean follow-up was 7.0 +/- 4.2 weeks. All the endpoints of interest significantly improved from baseline to the last follow-up: tear breakup time (p = 0.01), Ocular Surface Disease Index (p < 0.0001), Schirmer I test (p = 0.0001), and corneal staining (p < 0.0001). No difference was found in tear breakup time (p = 0.3), Ocular Surface Disease Index (p = 0.4), Schirmer I test (p = 0.3), and corneal staining (p = 0.3) between the honey-related treatment strategies and the control groups. According to our main results, honey-related treatment strategies are effective and feasible to improve symptoms and signs of DED.

Honey-related treatment strategies in dry eye disease / Prinz, Julia; Maffulli, Nicola; Fuest, Matthias; Walter, Peter; Hildebrand, Frank; Migliorini, Filippo. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 16:5(2023). [10.3390/ph16050762]

Honey-related treatment strategies in dry eye disease

Nicola Maffulli
;
2023

Abstract

This systematic review and meta-analysis investigated whether honey-related treatment strategies improve the signs and symptoms of patients with dry eye disease (DED). In March 2023, the following databases were accessed for clinical trials investigating the efficacy of honey-related treatment strategies in DED: PubMed, Web of Science, Google Scholar, and EMBASE. The following data were extracted at baseline and at the last follow-up: Ocular Surface Disease Index, tear breakup time, Schirmer I test, and corneal staining. Data from 323 patients were retrieved (53.3% female, mean age 40.6 +/- 18.1 years). The mean follow-up was 7.0 +/- 4.2 weeks. All the endpoints of interest significantly improved from baseline to the last follow-up: tear breakup time (p = 0.01), Ocular Surface Disease Index (p < 0.0001), Schirmer I test (p = 0.0001), and corneal staining (p < 0.0001). No difference was found in tear breakup time (p = 0.3), Ocular Surface Disease Index (p = 0.4), Schirmer I test (p = 0.3), and corneal staining (p = 0.3) between the honey-related treatment strategies and the control groups. According to our main results, honey-related treatment strategies are effective and feasible to improve symptoms and signs of DED.
2023
Manuka; royal Jelly; dry eye disease; honey; keratoconjunctivitis sicca; xerophthalmus
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Honey-related treatment strategies in dry eye disease / Prinz, Julia; Maffulli, Nicola; Fuest, Matthias; Walter, Peter; Hildebrand, Frank; Migliorini, Filippo. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 16:5(2023). [10.3390/ph16050762]
File allegati a questo prodotto
File Dimensione Formato  
Prinz_Honey-related_2023.pdf

accesso aperto

Note: review
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 3.04 MB
Formato Adobe PDF
3.04 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1699721
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact